Status:
UNKNOWN
Relative Dose Intensity of Adjuvant Chemotherapy in Older Women With ER+ HER2- Breast Cancer.
Lead Sponsor:
Centre Hospitalier Universitaire de Besancon
Conditions:
Breast Cancer
Eligibility:
FEMALE
75+ years
Brief Summary
Localized breast cancers are defined as high-risk when they include lymph node involvement, Ki67 \>30%, vascular emboli, low hormone receptor expression, or an unfavorable genomic signature result. U...
Eligibility Criteria
Inclusion
- Women aged 75 or over
- Patient with localized RH+HER2- breast cancer
- Patient treated with adjuvant chemotherapy in Franche Comté between January 2012 and December 2019
Exclusion
- Age \< 75
- Patient with metastatic breast cancer
- Patient who received neoadjuvant chemotherapy
- HER2+ breast cancer patient
- Breast cancer patient with missing or negative hormonal status
- Patient with localized recurrence of breast cancer with indication for new adjuvant therapy
Key Trial Info
Start Date :
September 20 2023
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
June 20 2025
Estimated Enrollment :
70 Patients enrolled
Trial Details
Trial ID
NCT06010615
Start Date
September 20 2023
End Date
June 20 2025
Last Update
September 7 2023
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.